Clinical trial details

A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours (TROPION-PanTumor03)

Identifier

D926UC00001/Endometri

Sponsor

ASTRAZENECA PHARMACEUTICALS, LP

Principal Investigator

ANA OAKNIN BENZAQUEN

Service

Oncology

Study details

Tumor type: ENDOMETRIUM
Stage: Advanced
Main Investigational Agent : ADC
Phase: II
Randomization: Non-randomized

Molecular details

Biomarker: Not applicable
Biomarker criteria: Not applicable
Prescreening: Not applicable
Additional study population requirements: Not applicable

Drug details

Arm A: Datopotamab deruxtecan (Dato-DXd)

Links

Clinical Trials GOV (NCT identifier): NCT05489211
EU Clinical Trials Register (eudraCT Identifier): 2022-000776-19